To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric cancer/adenocarcinoma of the gastroesophageal junction.
Patients voluntarily enrolled in the study and signed an informed consent form
18-75 years old, male and female gender are not limited
Gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction as determined by pathologic histology
Clinical staging of II-III/T3-4aNxM0 (AJCC 8th edition cTNM staging of gastric cancer)
patients who are pregnant or breastfeeding
Received prior anti-tumor therapy, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy
other malignant tumor (except basal or squamous cell carcinoma, superficial bladder cancer, cervical cancer in situ or breast cancer) within the past 5 years
Uncontrolled pleural effusion, pericardial effusion or ascites